Ca2+/calmodulin-dependent inhibitors of adenylyl cyclase 1 as novel nonopioid analgesics for chronic inflammatory pain
Molecular Pharmacology · 2026-05 · 108 (5-6) · 100121
DOI: 10.1016/j.molpha.2026.100121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmacology, 2026-05. Verfasst von Tiffany S Dwyer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana. Hauptthemen laut MEDLINE: Chronic Pain, Adenylyl Cyclases, Adenylyl Cyclase Inhibitors, Calcium. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NINDS NIH HHS, National Institute of Mental Health.
Abstract (Originalsprache)
Adenylyl cyclase 1 (AC1) plays an integral role in the excitatory signaling in the anterior cingulate cortex underlying chronic pain pathophysiology. Upon chronic nociceptive input, sustained Ca2+/calmodulin (CaM)-stimulated AC1 activity leads to the development of chronic pain. In this study, we characterize our recently reported series of pyrazolopyrimidinone amine analogs that selectively inhibit Ca2+/CaM-stimulated AC1 activity. Lead compounds AC10136A, AC10142A, and AC10172A exhibited potent AC1 inhibition (IC50 = 140—290 nM) and complete selectivity over AC2, AC5, and AC8. All compounds showed high therapeutic indices (>300) and minimal cytotoxicity up to 100 μM. Lead compounds displayed no functional agonism at κ-opioid receptor. Further, compounds prevented and reversed μ-opioid receptor—mediated heterologous sensitization of AC1, highlighting potential utility in mitigating opioid-induced dependence. Further, chronic treatment with lead compounds failed to induce opioid-like adaptations, such as heterologous sensitization, and did not modulate expression of AC1. Mechanistic studies revealed that inhibition is Ca2+/CaM dependent but independent of Gαs, suggesting preferential targeting of the active AC1 conformation. In mice, AC10142A demonstrated analgesic efficacy in the complete Freund adjuvant model of chronic inflammatory pain. Acute and repeated dosing at 48—120 h after complete Freund adjuvant treatment increased mechanical paw withdrawal thresholds and sustained analgesia over this repeated dosing. By targeting Ca2+/CaM-bound AC1, these inhibitors preferentially inhibit increased AC1 activity to its normal activity, demonstrating a state-dependent mechanism ideal for chronic pain treatment. Together, these findings establish AC10136A, AC10142A, and AC10172A as potent, selective, and well-tolerated AC1 inhibitors, with promising therapeutic potential for chronic pain and potentially opioid use disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana.
- Department of Biology, University of Copenhagen, Nørregade, Copenhagen, Denmark.
- Department of Pharmacology and Toxicology, University at Buffalo, Buffalo, New York; Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Duluth, Minnesota.
- Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, Indiana; Office of the Executive Vice President for Research, Purdue University, Purdue University, West Lafayette, Indiana.
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana; Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, Indiana; P…
Förderung
- NIDA NIH HHS
- NINDS NIH HHS
- National Institute of Mental Health
- National Institutes of Health
Zitieren
APA
Dwyer, T. S., Shrinidhi, A., Aryal, S., Berchtold, M. W., Munk, M., Klein, A. H., Koss, W. A., Flaherty, D. P., & Watts, V. J. (2026). Ca2+/calmodulin-dependent inhibitors of adenylyl cyclase 1 as novel nonopioid analgesics for chronic inflammatory pain. Molecular Pharmacology, 108(5-6), 100121. https://doi.org/10.1016/j.molpha.2026.100121
Vancouver
Dwyer TS, Shrinidhi A, Aryal S, Berchtold MW, Munk M, Klein AH, et al. Ca2+/calmodulin-dependent inhibitors of adenylyl cyclase 1 as novel nonopioid analgesics for chronic inflammatory pain. Molecular Pharmacology. 2026;108(5-6):100121. doi:10.1016/j.molpha.2026.100121
BibTeX
@article{Dwyer2026,
author = {Dwyer, Tiffany S and Shrinidhi, Annadka and Aryal, Sadikshya and Berchtold, Martin W and Munk, Mads and Klein, Amanda H and Koss, Wendy A and Flaherty, Daniel P and Watts, Val J},
title = {Ca2+/calmodulin-dependent inhibitors of adenylyl cyclase 1 as novel nonopioid analgesics for chronic inflammatory pain},
journal = {Molecular Pharmacology},
year = {2026},
volume = {108},
number = {5-6},
pages = {100121},
doi = {10.1016/j.molpha.2026.100121}
}
EUVIMED